Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.

Williams M, Cheng YY, Kirschner MB, Sarun KH, Schelch K, Winata P, McCaughan B, Kao S, Van Zandwijk N, Reid G.

Oncotarget. 2019 Jun 25;10(41):4125-4138. doi: 10.18632/oncotarget.27010. eCollection 2019 Jun 25.

2.

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.

Kresoja-Rakic J, Szpechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E.

Noncoding RNA. 2019 Jun 17;5(2). pii: E41. doi: 10.3390/ncrna5020041.

3.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

4.

Molecular Research in Chronic Thromboembolic Pulmonary Hypertension.

Opitz I, Kirschner MB.

Int J Mol Sci. 2019 Feb 12;20(3). pii: E784. doi: 10.3390/ijms20030784. Review.

5.

A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis.

Vafaee F, Diakos C, Kirschner MB, Reid G, Michael MZ, Horvath LG, Alinejad-Rokny H, Cheng ZJ, Kuncic Z, Clarke S.

NPJ Syst Biol Appl. 2018 Jun 1;4:20. doi: 10.1038/s41540-018-0056-1. eCollection 2018.

6.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
7.

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

Linton A, Cheng YY, Griggs K, Schedlich L, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G.

Br J Cancer. 2018 Mar 20;118(6):e13. doi: 10.1038/bjc.2018.3. Epub 2018 Feb 13.

8.

Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.

Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G.

J Thorac Oncol. 2018 Feb;13(2):258-272. doi: 10.1016/j.jtho.2017.10.016. Epub 2017 Nov 4.

9.

A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.

Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G.

Mol Oncol. 2018 Jan;12(1):58-73. doi: 10.1002/1878-0261.12150. Epub 2017 Nov 18.

10.

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.

J Thorac Oncol. 2017 Sep;12(9):1421-1433. doi: 10.1016/j.jtho.2017.05.024. Epub 2017 Jun 16. Erratum in: J Thorac Oncol. 2018 Apr;13(4):587.

11.

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.

Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, Weder W, Stahel RA, Felley-Bosco E.

Front Genet. 2017 May 29;8:70. doi: 10.3389/fgene.2017.00070. eCollection 2017.

12.

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.

Robles AI, Olsen KS, Tsui DW, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD.

J Transl Med. 2016 Oct 19;14(1):295.

13.

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.

Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G.

Genom Data. 2016 Jun 20;9:44-9. doi: 10.1016/j.gdata.2016.06.009. eCollection 2016 Sep.

14.

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.

Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B.

Eur J Cancer. 2016 Aug;63:64-73. doi: 10.1016/j.ejca.2016.04.018. Epub 2016 Jun 8.

PMID:
27288871
15.

KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.

Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.

Mol Cancer. 2016 Jun 1;15(1):44. doi: 10.1186/s12943-016-0529-z.

16.

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.

Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy MP, van Zandwijk N, Reid G.

Br J Cancer. 2016 Mar 1;114(5):524-31. doi: 10.1038/bjc.2015.470. Epub 2016 Feb 18.

17.

Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s.

Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, Hoffman H, Hesdorffer M, Nasu M, Napolitano A, Powers A, Minaai M, Baumann F, Bryant-Greenwood P, Lauk O, Kirschner MB, Weder W, Opitz I, Pass HI, Gaudino G, Pastorino S, Yang H.

PLoS Genet. 2015 Dec 18;11(12):e1005633. doi: 10.1371/journal.pgen.1005633. eCollection 2015 Dec.

18.

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJ, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G.

Br J Cancer. 2015 Sep 15;113(6):963-9. doi: 10.1038/bjc.2015.286. Epub 2015 Aug 11.

19.

miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RC, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G.

Oncotarget. 2015 Sep 15;6(27):23480-95.

20.

Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.

Birnie KA, Yip YY, Ng DC, Kirschner MB, Reid G, Prêle CM, Musk AW, Lee YC, Thompson PJ, Mutsaers SE, Badrian B.

Mol Cancer Res. 2015 Jul;13(7):1106-18. doi: 10.1158/1541-7786.MCR-14-0442. Epub 2015 Mar 30.

21.

MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Kirschner MB, Cheng YY, Armstrong NJ, Lin RC, Kao SC, Linton A, Klebe S, McCaughan BC, van Zandwijk N, Reid G.

Mol Oncol. 2015 Mar;9(3):715-26. doi: 10.1016/j.molonc.2014.11.007. Epub 2014 Dec 2.

22.

ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.

Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.

J Thorac Oncol. 2013 Oct;8(10):1317-28. doi: 10.1097/JTO.0b013e3182a0840a.

23.

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

Linton A, Cheng YY, Griggs K, Schedlich L, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G.

Br J Cancer. 2014 Jan 21;110(2):510-9. doi: 10.1038/bjc.2013.731. Epub 2013 Dec 10. Erratum in: Br J Cancer. 2018 Feb 13;:.

24.

Does miR-1 play a role in malignant pleural mesothelioma development and progression?

Wright CM, Kirschner MB, van Zandwijk N, Reid G.

Chest. 2013 Dec;144(6):1971. doi: 10.1378/chest.13-1657. No abstract available.

PMID:
24297134
25.

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N.

Ann Oncol. 2013 Dec;24(12):3128-35. doi: 10.1093/annonc/mdt412. Epub 2013 Oct 22.

26.

Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).

Wright CM, Kirschner MB, Cheng YY, O'Byrne KJ, Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van Zandwijk N, Reid G.

PLoS One. 2013 Aug 19;8(8):e70940. doi: 10.1371/journal.pone.0070940. eCollection 2013.

27.

The Impact of Hemolysis on Cell-Free microRNA Biomarkers.

Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G.

Front Genet. 2013 May 24;4:94. doi: 10.3389/fgene.2013.00094. eCollection 2013.

28.

Cell-free microRNAs: potential biomarkers in need of standardized reporting.

Kirschner MB, van Zandwijk N, Reid G.

Front Genet. 2013 Apr 19;4:56. doi: 10.3389/fgene.2013.00056. eCollection 2013.

29.

Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.

Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, Armstrong NJ, Vallely MP, Musk AW, Robinson BW, McCaughan BC, Klebe S, Mutsaers SE, van Zandwijk N, Reid G.

J Thorac Oncol. 2012 Jul;7(7):1184-91. doi: 10.1097/JTO.0b013e3182572e83.

30.

Haemolysis during sample preparation alters microRNA content of plasma.

Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G.

PLoS One. 2011;6(9):e24145. doi: 10.1371/journal.pone.0024145. Epub 2011 Sep 1.

31.

Circulating microRNAs: Association with disease and potential use as biomarkers.

Reid G, Kirschner MB, van Zandwijk N.

Crit Rev Oncol Hematol. 2011 Nov;80(2):193-208. doi: 10.1016/j.critrevonc.2010.11.004. Epub 2010 Dec 8. Review.

PMID:
21145252

Supplemental Content

Loading ...
Support Center